Diabetes Care, Vol 23, Issue 6 813-819, Copyright © 2000 by American Diabetes Association

ARTICLES

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites

DR Owens, PA Coates, SD Luzio, JP Tinbergen and R Kurzhals
University of Wales College of Medicine, Diabetes Research Unit, Academic Centre, Llandough Hospital, Penarth, South Glamorgan, UK.

OBJECTIVE: To determine the subcutaneous absorption rates and the appearance in plasma of 3 formulations of the long-acting human insulin analog insulin glargine (HOE 901) differing only in zinc content (15, 30, and 80 microg/ml). RESEARCH DESIGN AND METHODS: We conducted 2 studies. Study 1 compared the subcutaneous abdominal injection of 0.15 U/kg of 125I-labeled insulin glargine[15], insulin glargine[80], NPH insulin, and placebo. In study 2, 0.2 U/kg of insulin glargine[30] was injected into the arm, leg, and abdominal regions. Both studies had a randomized crossover design; each enrolled 12 healthy men, aged 18-50 years. RESULTS: In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001). Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001). The calculated plasma exogenous insulin concentrations after NPH insulin were substantially higher than those with insulin glargine, reaching a peak within the first 6 h after administration before declining. Insulin glargine, however, did not exhibit a distinct peak. Weighted average plasma glucose concentration between 0 and 6 h was significantly lower after NPH compared with insulin glargine (P < 0.001). In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h. CONCLUSIONS: Subcutaneous absorption of insulin glargine is delayed compared with NPH insulin. There is little or no difference in the absorption rate of insulin glargine between the main subcutaneous injection sites.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Kota, K. K. Machavaram, D. N. McLennan, G. A. Edwards, C. J. H. Porter, and S. A. Charman Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model Drug Metab. Dispos., December 1, 2007; 35(12): 2211 - 2217. [Abstract] [Full Text] [PDF]

				F. Porcellati, P. Rossetti, N. B. Ricci, S. Pampanelli, E. Torlone, S. H. Campos, A. M. Andreoli, G. B. Bolli, and C. G. Fanelli Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes Diabetes Care, May 1, 2007; 30(5): 1261 - 1263. [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				J. Plank, M. Bodenlenz, F. Sinner, C. Magnes, E. Gorzer, W. Regittnig, L. A. Endahl, E. Draeger, M. Zdravkovic, and T. R. Pieber A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir Diabetes Care, May 1, 2005; 28(5): 1107 - 1112. [Abstract] [Full Text] [PDF]

				J. Rosenstock, G. Dailey, M. Massi-Benedetti, A. Fritsche, Z. Lin, and A. Salzman Reduced Hypoglycemia Risk With Insulin Glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care, April 1, 2005; 28(4): 950 - 955. [Abstract] [Full Text] [PDF]

				R. Peter, S. D. Luzio, G. Dunseath, A. Miles, B. Hare, K. Backx, V. Pauvaday, and D. R. Owens Effects of Exercise on the Absorption of Insulin Glargine in Patients With Type 1 Diabetes Diabetes Care, March 1, 2005; 28(3): 560 - 565. [Abstract] [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				P. Home, P. Bartley, D. Russell-Jones, H. Hanaire-Broutin, J.-E. Heeg, P. Abrams, M. Landin-Olsson, B. Hylleberg, H. Lang, and E. Draeger Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial Diabetes Care, May 1, 2004; 27(5): 1081 - 1087. [Abstract] [Full Text] [PDF]

				T. Danne, K. Lupke, K. Walte, W. von Schuetz, and M.-A. Gall Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes Diabetes Care, November 1, 2003; 26(11): 3087 - 3092. [Abstract] [Full Text] [PDF]

				R. Gadsby Using insulin earlier in the treatment of type 2 diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2003; 3(2): 119 - 122. [Abstract] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]